Sorrento Therapeutics, Inc. Stock price

Equities

SRNEQ

US83587F2020

Biotechnology & Medical Research

Market Closed - OTC Markets 03:57:57 2024-03-27 pm EDT 5-day change 1st Jan Change
0.008 USD -11.11% Intraday chart for Sorrento Therapeutics, Inc. -60.00% -93.52%
Sales 2021 52.9M Sales 2022 62.84M Capitalization 411M
Net income 2021 -428M Net income 2022 -573M EV / Sales 2021 29.1 x
Net Debt 2021 111M Net Debt 2022 84.53M EV / Sales 2022 7.89 x
P/E ratio 2021
-3.2 x
P/E ratio 2022
-0.65 x
Employees 949
Yield 2021 *
-
Yield 2022
-
Free-Float 97.77%
More Fundamentals * Assessed data
Dynamic Chart
1 day-11.11%
1 week-60.00%
Current month-70.37%
1 month-70.04%
3 months-93.64%
6 months-91.21%
Current year-93.52%
More quotes
1 week
0.01
Extreme 0.0055
0.02
1 month
0.01
Extreme 0.0055
0.03
Current year
0.00
Extreme 0.001
0.14
1 year
0.00
Extreme 0.001
0.42
3 years
0.00
Extreme 0.001
11.07
5 years
0.00
Extreme 0.001
19.39
10 years
0.00
Extreme 0.001
26.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 88-12-31
Chief Operating Officer - -
Chief Tech/Sci/R&D Officer 70 14-03-02
Members of the board TitleAgeSince
Director/Board Member 67 12-03-31
Director/Board Member 61 17-09-30
Director/Board Member 63 13-09-10
More insiders
Date Price Change Volume
24-03-27 0.008 -11.11% 210,550
24-03-26 0.009 0.00% 153,597
24-03-25 0.009 +12.50% 61,686
24-03-22 0.008 0.00% 103,819
24-03-21 0.008 -60.00% 355,232

Delayed Quote OTC Markets, March 27, 2024 at 03:57 pm EDT

More quotes
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company's immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock
  2. Equities
  3. Stock Sorrento Therapeutics, Inc. - OTC Markets